Goldman Sachs Downgrades Lantheus (LNTH) PT to $77 Amid PYLARIFY Pricing Pressure, Slow Alzheimer's Drug Uptake

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the best value stocks to invest in now. On October 8, Goldman Sachs downgraded Lantheus to Neutral from Buy with a price target of $77, down from $110. The firm believes that the stock has underperformed year-to-date due to pricing pressure on PYLARIFY and slower-than-anticipated uptake of approved Alzheimer’s disease therapeutics.

Additionally, in Q2 2025, the company made $378.05 million in sales, which was a modest drop of 4.07% year-over-year. Before this downgrade on September 24, Lantheus and GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced an exclusive licensing agreement for the prostate cancer imaging agent, PYLARIFY. Under the agreement, GE HealthCare will develop, manufacture, and commercialize the agent in Japan for prostate cancer diagnostics and companion diagnostic use.

Furthermore, earlier this year, Lantheus announced that its clinical-stage F18-labeled tau Positron Emission Tomography/PET radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies. This confirmed the high sensitivity and specificity of MK-6240 as a diagnostic tool for Alzheimer’s disease.

Lantheus Holdings Inc. (NASDAQ:LNTH) develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.